NL0015285941 - IMTX - A2P72S (XNAS)
IMMATICS NV- Aktie
12,76 USD
Aktuelle Kurse von IMMATICS NV-
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
IMTX
|
USD
|
19.09.2024 23:51
|
12,76 USD
| 12,19 USD | 4,68 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | 0,63 % | 11,64 % | 1,43 % | 9,43 % | 3,15 % | 25,10 % |
Firmenprofil zu IMMATICS NV- Aktie
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Unternehmensdaten zur IMMATICS NV- Aktie
Name IMMATICS NV-
Firma Immatics N.V.
Symbol IMTX
Website https://www.immatics.com
Heimatbörse
NASDAQ
WKN A2P72S
ISIN NL0015285941
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Harpreet Singh Ph.D.
Marktkapitalisierung 1 Mrd.
Land Deutschland
Währung USD
Mitarbeiter 0,5 T
Adresse Paul-Ehrlich-Strasse 15, 72076 Tübingen
IPO Datum 2018-12-12
Aktien Kennungs-Wechsel
Datum | Von | Zu |
---|---|---|
02.07.2020 | ARYA | IMTX |
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | 4A3.F |
NASDAQ | IMTX |
Weitere Aktien
Investoren die IMMATICS NV- halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024